Medifast Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Medifast stock.
View analyst ratings for Medifast or view top-rated stocks.

Wall Street analysts have given Medifast a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Medifast wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Medifast is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Medifast.

Medifast will be holding an earnings conference call on Wednesday, August 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 877-344-7529 with passcode "10158283".

Medifast, Inc. (NYSE:MED) issued its quarterly earnings results on Tuesday, May, 4th. The specialty retailer reported $3.46 EPS for the quarter, beating the Zacks' consensus estimate of $2.72 by $0.74. The specialty retailer earned $340.70 million during the quarter, compared to analysts' expectations of $279.12 million. Medifast had a net margin of 11.44% and a trailing twelve-month return on equity of 85.97%. The company's quarterly revenue was up 90.9% compared to the same quarter last year.
View Medifast's earnings history.

Medifast's stock was trading at $70.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MED shares have increased by 297.0% and is now trading at $279.63.
View which stocks have been most impacted by COVID-19.

Medifast announced a quarterly dividend on Thursday, June 3rd. Stockholders of record on Tuesday, June 22nd will be paid a dividend of $1.42 per share on Friday, August 6th. This represents a $5.68 annualized dividend and a dividend yield of 2.03%. The ex-dividend date is Monday, June 21st.
View Medifast's dividend history.

Medifast pays an annual dividend of $5.68 per share and currently has a dividend yield of 2.02%. Medifast does not yet have a strong track record of dividend growth. The dividend payout ratio of Medifast is 62.14%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Medifast will have a dividend payout ratio of 36.36% next year. This indicates that Medifast will be able to sustain or increase its dividend.
View Medifast's dividend history.

Medifast updated its FY 2021 earnings guidance on Tuesday, May, 25th. The company provided earnings per share guidance of 12.690-14.140 for the period, compared to the Thomson Reuters consensus estimate of $11.110. The company issued revenue guidance of $1.40 billion-$1.48 billion, compared to the consensus revenue estimate of $1.19 billion.

3 equities research analysts have issued 1 year price objectives for Medifast's stock. Their forecasts range from $265.00 to $400.00. On average, they anticipate Medifast's share price to reach $353.33 in the next year. This suggests a possible upside of 26.4% from the stock's current price.
View analysts' price targets for Medifast or view top-rated stocks among Wall Street analysts.

44 employees have rated Medifast CEO Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among Medifast's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Medifast include The Estée Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Prestige Consumer Healthcare (PBH), Inter Parfums (IPAR), USANA Health Sciences (USNA), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR).
View all of MED's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), The Home Depot (HD), The Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast's stock is owned by a variety of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.07%), Brookstone Capital Management (0.01%), SkyOak Wealth LLC (0.01%) and 6 Meridian (0.01%). Company insiders that own Medifast stock include Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends for Medifast.

MED stock was bought by a variety of institutional investors in the last quarter, including Brookstone Capital Management, SkyOak Wealth LLC, 6 Meridian, and State of Alaska Department of Revenue.
View insider buying and selling activity for Medifast or or view top insider-buying stocks.

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MED stock can currently be purchased for approximately $279.63.

Medifast has a market capitalization of $3.29 billion and generates $934.84 million in revenue each year. The specialty retailer earns $102.86 million in net income (profit) each year or $9.14 on an earnings per share basis.

Medifast employs 713 workers across the globe.

The official website for Medifast is www.medifast1.com.

Medifast is headquartered at 100 International Drive, Baltimore MD, 21202.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]